LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
01 2020
Historique:
received: 28 01 2019
accepted: 09 08 2019
revised: 08 07 2019
pubmed: 30 8 2019
medline: 21 4 2020
entrez: 30 8 2019
Statut: ppublish

Résumé

Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function. We find that LOXL2 and H3K4ox are higher in triple-negative breast cancer (TNBC) cell lines and patient-derived xenografts (PDXs) than those from other breast cancer subtypes. ChIP-seq revealed that H3K4ox is located primarily in heterochromatin, where it is involved in chromatin compaction. Knocking down LOXL2 reduces H3K4ox levels and causes chromatin decompaction, resulting in a sustained activation of the DNA damage response (DDR) and increased susceptibility to anticancer agents. This critical role that LOXL2 and oxidized H3 play in chromatin compaction and DDR suggests that functionally targeting LOXL2 could be a way to sensitize TNBC cells to conventional therapy.

Identifiants

pubmed: 31462706
doi: 10.1038/s41388-019-0969-1
pii: 10.1038/s41388-019-0969-1
pmc: PMC6937214
doi:

Substances chimiques

Chromatin 0
Heterochromatin 0
Histones 0
Amino Acid Oxidoreductases EC 1.4.-
LOXL2 protein, human EC 1.4.3.-
Lysine K3Z4F929H6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-121

Références

Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21:381–95.
pubmed: 21321607 pmcid: 21321607
Williamson PR, Kagan HM. Reaction pathway of bovine aortic lysyl oxidase. J Biol Chem. 1986;261:9477–82.
pubmed: 2873143
Herranz N, Dave N, Millanes-Romero A, Pascual-Reguant L, Morey L, Diaz VM, et al. Lysyl oxidasE−like 2 (LOXL2) oxidizes trimethylated lysine 4 in histone H3. FEBS J. 2016;283:4263–73.
pubmed: 27735137
Iturbide A, Garcia de Herreros A, Peiro S. A new role for LOX and LOXL2 proteins in transcription regulation. FEBS J. 2015;282:1768–73.
pubmed: 25103872
Iturbide A, Pascual-Reguant L, Fargas L, Cebria JP, Alsina B, Garcia de Herreros A, et al. LOXL2 oxidizes methylated TAF10 and controls TFIID-dependent genes during neural progenitor differentiation. Mol Cell. 2015;58:755–66.
pubmed: 25959397
Millanes-Romero A, Herranz N, Perrera V, Iturbide A, Loubat-Casanovas J, Gil J, et al. Regulation of heterochromatin transcription by Snail1/LOXL2 during epithelial-to-mesenchymal transition. Mol Cell. 2013;52:746–57.
pubmed: 24239292
Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. Nat Rev Cancer. 2012;12:540–52.
pubmed: 22810810
Cano A, Santamaria PG, Moreno-Bueno G. LOXL2 in epithelial cell plasticity and tumor progression. Future Oncol. 2012;8:1095–108.
pubmed: 23030485
Ahn SG, Dong SM, Oshima A, Kim WH, Lee HM, Lee SA, et al. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Breast Cancer Res Treat. 2013;141:89–99.
pubmed: 23933800
Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014;6:514–27.
pubmed: 24462293 pmcid: 3928845
De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.
pubmed: 23344542
Escriva M, Peiro S, Herranz N, Villagrasa P, Dave N, Montserrat-Sentis B, et al. Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol. 2008;28:1528–40.
pubmed: 18172008 pmcid: 2258777
Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I, Nieto MA. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 2004;18:1131–43.
pubmed: 15155580 pmcid: 415638
McDonald OG, Wu H, Timp W, Doi A, Feinberg AP. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol. 2011;18:867–74.
pubmed: 21725293 pmcid: 3150339
Peinado H, Moreno-Bueno G, Hardisson D, Perez-Gomez E, Santos V, Mendiola M, et al. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Cancer Res. 2008;68:4541–50.
pubmed: 18559498
Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, Dave N, et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol. 2008;28:4772–81.
pubmed: 18519590 pmcid: 2493371
Bekker-Jensen S, Lukas C, Kitagawa R, Melander F, Kastan MB, Bartek J, et al. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J Cell Biol. 2006;173:195–206.
pubmed: 16618811 pmcid: 2063811
Soutoglou E, Misteli T. Activation of the cellular DNA damage response in the absence of DNA lesions. Science. 2008;320:1507–10.
pubmed: 18483401 pmcid: 2575099
Bonilla CY, Melo JA, Toczyski DP. Colocalization of sensors is sufficient to activate the DNA damage checkpoint in the absence of damage. Mol Cell. 2008;30:267–76.
pubmed: 18471973 pmcid: 2879338
Gursoy-Yuzugullu O, House N, Price BD. Patching broken DNA: nucleosome dynamics and the repair of DNA breaks. J Mol Biol. 2016;428:1846–60.
pubmed: 26625977
Ziv Y, Bielopolski D, Galanty Y, Lukas C, Taya Y, Schultz DC, et al. Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway. Nat Cell Biol. 2006;8:870–6.
pubmed: 16862143
Burgess RC, Burman B, Kruhlak MJ, Misteli T. Activation of DNA damage response signaling by condensed chromatin. Cell Rep. 2014;9:1703–17.
pubmed: 25464843 pmcid: 4267891
Ayrapetov MK, Gursoy-Yuzugullu O, Xu C, Xu Y, Price BD. DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin. Proc Natl Acad Sci USA. 2014;111:9169–74.
pubmed: 24927542
Khurana S, Kruhlak MJ, Kim J, Tran AD, Liu J, Nyswaner K, et al. A macrohistone variant links dynamic chromatin compaction to BRCA1-dependent genome maintenance. Cell Rep. 2014;8:1049–62.
pubmed: 25131201 pmcid: 4154351
Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13:215.
pubmed: 21884641 pmcid: 3236329
Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137.
pubmed: 18798982 pmcid: 18798982
Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nat Methods. 2012;9:215–6.
pubmed: 22373907 pmcid: 3577932
Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods. 2013;10:1213–8.
pubmed: 24097267 pmcid: 3959825
Tsompana M, Buck MJ. Chromatin accessibility: a window into the genome. Epigenetics Chromatin. 2014;7:33.
pubmed: 25473421 pmcid: 4253006
Burgess RC, Misteli T. Not all DDRs are created equal: non-canonical DNA damage responses. Cell. 2015;162:944–7.
pubmed: 26317463 pmcid: 4560361
Bayona-Feliu A, Casas-Lamesa A, Reina O, Bernues J, Azorin F. Linker histone H1 prevents R-loop accumulation and genome instability in heterochromatin. Nat Commun. 2017;8:283.
pubmed: 28819201 pmcid: 5561251
Tuduri S, Crabbe L, Conti C, Tourriere H, HoltgrevE−Grez H, Jauch A, et al. Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol. 2009;11:1315–24.
pubmed: 19838172 pmcid: 2912930
Garcia-Rubio ML, Perez-Calero C, Barroso SI, Tumini E, Herrera-Moyano E, Rosado IV, et al. The Fanconi anemia pathway protects genome integrity from R-loops. PLoS Genet. 2015;11:e1005674.
pubmed: 26584049 pmcid: 4652862
Gan W, Guan Z, Liu J, Gui T, Shen K, Manley JL, et al. R-loop-mediated genomic instability is caused by impairment of replication fork progression. Genes Dev. 2011;25:2041–56.
pubmed: 21979917 pmcid: 3197203
Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421:499–506.
pubmed: 12556884
Kaidi A, Jackson SP. KAT5 tyrosine phosphorylation couples chromatin sensing to ATM signalling. Nature. 2013;498:70–4.
pubmed: 23708966
Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990;265:17174–9.
pubmed: 2211619
Toth KF, Knoch TA, Wachsmuth M, Frank-Stohr M, Stohr M, Bacher CP, et al. Trichostatin A-induced histone acetylation causes decondensation of interphase chromatin. J Cell Sci. 2004;117:4277–87.
pubmed: 15292402
Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D, Csiszar K, Fong KS, Vega S, et al. A molecular role for lysyl oxidasE−like 2 enzyme in snail regulation and tumor progression. EMBO J. 2005;24:3446–58.
pubmed: 16096638 pmcid: 1276164
Schietke R, Warnecke C, Wacker I, Schodel J, Mole DR, Campean V, et al. The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. J Biol Chem. 2010;285:6658–69.
pubmed: 20026874
Voloshenyuk TG, Landesman ES, Khoutorova E, Hart AD, Gardner JD. Induction of cardiac fibroblast lysyl oxidase by TGF-beta1 requires PI3K/Akt, Smad3, and MAPK signaling. CytoAbsorbance was detected atkine. 2011;55:90–7.
Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527:472–6.
pubmed: 26560033 pmcid: 26560033
Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527:525–30.
pubmed: 26560028 pmcid: 26560028
Baldeyron C, Soria G, Roche D, Cook AJ, Almouzni G. HP1alpha recruitment to DNA damage by p150CAF-1 promotes homologous recombination repair. J Cell Biol. 2011;193:81–95.
pubmed: 21464229 pmcid: 3082177
Soria G, Polo SE, Almouzni G. Prime, repair, restore: the active role of chromatin in the DNA damage response. Mol Cell. 2012;46:722–34.
pubmed: 22749398
Murga M, Jaco I, Fan Y, Soria R, Martinez-Pastor B, Cuadrado M, et al. Global chromatin compaction limits the strength of the DNA damage response. J Cell Biol. 2007;178:1101–8.
pubmed: 17893239 pmcid: 2064646
Goodarzi AA, Noon AT, Deckbar D, Ziv Y, Shiloh Y, Lobrich M, et al. ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin. Mol Cell. 2008;31:167–77.
pubmed: 18657500
Fong SF, Dietzsch E, Fong KS, Hollosi P, Asuncion L, He Q, et al. Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors. Genes Chromosomes Cancer. 2007;46:644–55.
pubmed: 17394133
Moreno-Bueno G, Salvador F, Martin A, Floristan A, Cuevas EP, Santos V, et al. Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Mol Med. 2011;3:528–44.
pubmed: 21732535 pmcid: 3377095
Torres S, Garcia-Palmero I, Herrera M, Bartolome RA, Pena C, Fernandez-Acenero MJ, et al. LOXL2 is highly expressed in cancer-associated fibroblasts and associates to poor colon cancer survival. Clin Cancer Res. 2015;21:4892–902.
pubmed: 26206869
Wong CC, Tse AP, Huang YP, Zhu YT, Chiu DK, Lai RK, et al. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology. 2014;60:1645–58.
pubmed: 25048396
Martin A, Salvador F, Moreno-Bueno G, Floristan A, Ruiz-Herguido C, Cuevas EP, et al. Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression. EMBO J. 2015;34:1090–109.
pubmed: 25759215 pmcid: 4406654
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–60.
pubmed: 17051156
Wu M, Wang PF, Lee JS, Martin-Brown S, Florens L, Washburn M, et al. Molecular regulation of H3K4 trimethylation by Wdr82, a component of human Set1/COMPASS. Mol Cell Biol. 2008;28:7337–44.
pubmed: 18838538 pmcid: 2593441
Guelen L, Pagie L, Brasset E, Meuleman W, Faza MB, Talhout W, et al. Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. Nature. 2008;453:948–51.
pubmed: 18463634
Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25.
pubmed: 19261174 pmcid: 2690996
Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36.
pubmed: 23618408 pmcid: 4053844
Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7:562–78.
pubmed: 22383036 pmcid: 3334321
Lerat E, Fablet M, Modolo L, Lopez-Maestre H, Vieira C. TEtools facilitates big data expression analysis of transposable elements and reveals an antagonism between their activity and that of piRNA genes. Nucleic Acids Res. 2017;45:e17.
pubmed: 28204592
Tarazona S, Furio-Tari P, Turra D, Pietro AD, Nueda MJ, Ferrer A, et al. Data quality aware analysis of differential expression in RNA-seq with NOISeq R/Bioc package. Nucleic Acids Res. 2015;43:e140.
pubmed: 26184878 pmcid: 4666377
Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841–2.
pubmed: 20110278 pmcid: 2832824

Auteurs

J P Cebrià-Costa (JP)

Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.

L Pascual-Reguant (L)

Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.

A Gonzalez-Perez (A)

Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, 08028, Barcelona, Spain.

G Serra-Bardenys (G)

Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.

J Querol (J)

Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.

M Cosín (M)

Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.

G Verde (G)

Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.
Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain.

R A Cigliano (RA)

Sequentia Biotech SL, Comte d'Urgell, 240, Barcelona, Spain.

W Sanseverino (W)

Sequentia Biotech SL, Comte d'Urgell, 240, Barcelona, Spain.

S Segura-Bayona (S)

Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, 08028, Barcelona, Spain.

A Iturbide (A)

Institute of Epigenetics and Stem Cells, Helmoholtz Zentrum München, D-81377, München, Germany.

D Andreu (D)

Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.

P Nuciforo (P)

Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.

C Bernado-Morales (C)

Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.
Centro de Investigación Biomédica en Red en Oncología (CIBERONC), 08035, Barcelona, Spain.

V Rodilla (V)

Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.

J Arribas (J)

Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain.
Centro de Investigación Biomédica en Red en Oncología (CIBERONC), 08035, Barcelona, Spain.
Institució Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain.
Departament de Bioquímica y Biología Molecular, Universitat Autónoma de Barcelona, Bellaterra, Spain.

J Yelamos (J)

Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.

A Garcia de Herreros (AG)

Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.
Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain.

T H Stracker (TH)

Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, 08028, Barcelona, Spain.

S Peiró (S)

Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain. speiro@vhio.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH